Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Sunday, July 3, 2022

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Molderizer and Safe Shield

Pima County launches free program to expand COVID-19 antiviral access | Coronavirus

Global coronavirus cases cross 544.91 mln

WASHINGTON - The global COVID-19 case tally reached over 544.91 million with 6,746,636 deaths recorded to date, according to a Reuters tally on Saturday.The...

RPI gets $3.5M to develop COVID-19 antiviral drug

TROY, N.Y. (NEWS10) — Rensselaer Polytechnic Institute researchers have secured a five-year, $3.5 million grant to develop a low-dose, oral COVID antiviral drug that can be administered...

Japan’s secret to taming the coronavirus: peer pressure

To understand how Japan has fared better than most of the world in containing the dire consequences of the coronavirus pandemic, consider Mika...


TUCSON (KVOA) — Tucsonans now have a faster and easier way to access COVID-19 treatments after Pima County Health Department launched its free Test to Treat program at its east clinic on Thursday.

Created in partnership with the Federal Emergency Management Agency, people who test or have already tested positive for COVID-19 can be evaluated at the clinic located at 6920 E. Broadway Blvd. to see if they are eligible to receive COVID-19 treatment medication

County officials say the evaluation and the medication will come at no cost to visitors, and no insurance is required.

People who tested positive for the virus either at another testing site or by using an at-home test kit can either walk into the clinic for an evaluation or call 520-724-7895 to determine eligibility. 

According to the county, people who are potentially eligible to receive the treatment after testing positive for COVID-19 must meet the following criteria:

  • They are 12 or older
  • Weigh at least 88 pounds
  • Have mild to moderate symptoms
  • Have a high risk of severe COVID-19 illness

Officials say the medications offered at these sites are Pfizer’s Paxlovid and Merck’s Lagevrio, which are both effective five days after the individual experiences symptoms.

“This new program will help ensure that those who don’t have easy access to care, or can’t see their usual health care provider, can get the timely treatment they need after a COVID-19 infection,” said Pima County Health Department Director Dr. Theresa Cullen. “We’re thrilled to be able to offer this to everybody with the help of FEMA, which previously has been a great partner with COVID-19 vaccination and testing in our community.”

For more information on where to get tested for COVID-19 in Pima County, visit pima.gov/covid19testing.

People who would like more information about the county’s COVID-19 treatment, visit pima.gov/covid19treatment.

Have a news tip or would like to report a typo? Email Anthony Victor Reyes at areyes@kvoa.com.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Global coronavirus cases cross 544.91 mln

WASHINGTON - The global COVID-19 case tally reached over 544.91 million with 6,746,636 deaths recorded to date, according to a Reuters tally on Saturday.The...

RPI gets $3.5M to develop COVID-19 antiviral drug

TROY, N.Y. (NEWS10) — Rensselaer Polytechnic Institute researchers have secured a five-year, $3.5 million grant to develop a low-dose, oral COVID antiviral drug that can be administered...

Related Articles

Global coronavirus cases cross 544.91 mln

WASHINGTON - The global COVID-19 case tally reached over 544.91 million with 6,746,636 deaths recorded to date, according to a Reuters tally on Saturday.The...

RPI gets $3.5M to develop COVID-19 antiviral drug

TROY, N.Y. (NEWS10) — Rensselaer Polytechnic Institute researchers have secured a five-year, $3.5 million grant to develop a low-dose, oral COVID antiviral drug that can be administered...